© 2021 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
April 13, 2021
Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.
April 12, 2021
Learn more about what treatments are on the rise for plaque psoriasis, the latest management advice and what trends are shaping the future of the disease.
In this month's Cosmetic Conundrums column, Dermatology Times Chief Medical Editor Zoe Diana Draelos, MD, discusses how to solve common challenges associated with pierced earrings.
This week’s edition of The Mainstream Patient features stories on fraxel lasers, microcurrent facials, perioral dermatitis, brow lifts, plus more.
Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
April 09, 2021
ICYMI, some of this week’s featured content includes stories on the cyberwar against health care practices, the link between oxytocin and skin aging, baricitinib for alopecia areata, plus more.
Timber Pharmaceuticals's phase 2b trial of isotretinoin for congenital ichthyosis (CI) has reached 50% enrollment.
An array of agents for blocking visible light and lightening skin are joining the armamentarium to treat melasma. Despite this expanding number of therapeutic interventions, melasma is a chronic, therapeutically challenging disease for which there is no cure, so treatment plans should address both management of the disease and patient expectations.
April 08, 2021
Eli Lilly and Incyte announce results from its phase 3 study evaluating baricitinib 2 mg and 4 mg for the treatment of alopecia areata, making it the first Phase 3 study with top-line results in patients with the hair disorder.